Feb 10, 2022 7:36 am EST SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
Dec 20, 2021 8:30 am EST BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients
Dec 15, 2021 8:30 am EST European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS’ Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis
Dec 6, 2021 7:00 am EST SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis
Dec 1, 2021 10:37 am EST BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What’s New Award in the Health Category
